Time in suboptimal glycemic control over 10 years for patients newly diagnosed with type 2 diabetes
- PMID: 32499115
- DOI: 10.1016/j.jdiacomp.2020.107607
Time in suboptimal glycemic control over 10 years for patients newly diagnosed with type 2 diabetes
Abstract
Objective: To estimate time in suboptimal glycemic control among patients with incident type 2 diabetes (T2D) over 10 years.
Methods: We calculated percent of time in suboptimal glycemic control using three A1C thresholds (8%, 7.5%, 7%) following T2D diagnosis. Stratified analyses were conducted based on age and A1C levels at T2D diagnosis.
Results: We identified 28,315 patients with incident T2D. Percent of time in suboptimal glycemic control increased with T2D duration. Mean percent time in suboptimal A1C control in the first 2 years following diagnosis was 30%, 34% and 40% for the 8%, 7.5%, and 7% thresholds, respectively. In the 6-10 years following T2D diagnosis, the percent time in suboptimal A1C control increased to 39%, 48% and 61%, for the 8%, 7.5%, and 7% thresholds, respectively. Time in suboptimal glycemic control was longer among younger patients aged 20-44 versus ≥65 years and those with higher A1C (>8%) versus lower A1C (<7%) at diagnosis.
Conclusions: Over 10 years following diagnosis, T2D patients spent one-third to over one-half of their time in suboptimal glycemic control. Reducing time spent above desired A1C targets could lower risk of microvascular and macrovascular complications.
Keywords: Glycemic control; Hemoglobin A1c; Type 2 diabetes.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: J.A., K.R. are employees of Kaiser Permanente Southern California and G.A.N. is employee of Kaiser Permanente Northwest who received funding through their institutions from Merck & Co., Inc. for the conduct of this study. T.W., S.R. are employees of Merck & Co., Inc.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
